Mechanisms of immunization with a replication-defective mutant of herpes simplex virus

Virology

Volumn 220, Issue 2, 1996, Pages 402-413

  Morrison, Lynda A ^a,b   Knipe, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; DEFECTIVE VIRUSES; DISEASE MODELS, ANIMAL; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNIZATION; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; MUTATION; TIME FACTORS; TRIGEMINAL GANGLION; VACCINES, ATTENUATED; VERO CELLS; VIRAL PROTEINS; VIRAL VACCINES; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0029897416     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0328     Document Type: Article

References (60)

1. Babu, J. S., Thomas, J., Kanangat, S., Morrison, L. A., Knipe, D. M., and Rouse, B. T. (1996). Viral replication is required for induction of ocular immunopathology by herpes simplex virus. J. Virol. 70, 101-107.
2. Blacklaws, B. A., Krishna, S., Minson, A. C., and Nash, A. A. (1990). Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants. Virology 177, 727-736.
3. Burke, R. L., Hartog, K., Croen, K. D., and Ostrove, J. M. (1991). Detection and characterization of latent HSV RNA by in situ and northern blot hybridization in guinea pigs. Virology 181, 793-797.
4. Burke, R. L. (1992). Contemporary approaches to vaccination against herpes simplex virus. Curr. Top. Microbiol. Immunol. 179, 137-158.
5. Cantin, E. M., Eberle, R., Baldick, J. L., Moss, B., Willey, D. E., Notkins, A. L., and Openshaw, H. (1983). Expression of herpes simplex virus 1 glycoprotein B by a recombinant vacinia virus and protection of mice against lethal HSV-1 challenge. Proc. Natl. Acad. Sci. USA 80, 7155-7159.
6. Coen, D. M., Irmiere, A. F., Jacobson, J. G., and Kerns, K. M. (1989). Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168, 221-231.
7. Committee on Care and Use of Laboratory Animals. (1985). Guide for the care and use of laboratory animals. 85-23.
8. Cooney, E. L., McElrath, M. J., Corey, L., Hu, S.-L., Collier, A. C., Arditti, D., Hoffman, M., Coombs, R. W., Smith, G. E., and Greenberg, P. D. (1993). Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. USA 90, 1882-1886.
9. Corey, L. (1991). Clinical studies with herpes simplex virus type 2 Curtis strain vaccine. Rev. Infect. Dis. 13(Suppl. 11), S904-905.
10. Cox, W. I., Targaglia, J., and Paoletti, E. (1993). Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195, 845-850.
11. Cremer, K. J., Mackett, M., Wohlenberg, C., Notkins, A. L., and Moss, B. (1985). Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 228, 737-740.
12. Croen, K. D., Ostrove, J. M., Dragovic, L. J., Smialek, J. E., and Straus, S. E. (1987). Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene "anti-sense" transcript by in situ hybridization. N. Engl. J. Med. 317, 1427-1432.
13. Dix, R. D., and Mills, J. (1985). Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD. J. Med. Virol. 17, 9-18.
14. Farrell, H. E., McLean, C. S., Harley, C., Efstathiou, S., Inglis, S., and McLean, A. C. (1994). Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol. 68, 927-932.
15. Foster, C. S., Tsai, Y., Monroe, J. G., Campbell, R., Cestari, M., Wetzig, R., Knipe, D. M., and Greene, M. I. (1986). Genetic studies on murine susceptibility to herpes simplex keratitis. Clin. Immunol. Immunopathol. 40, 313-325.
16. Gallichan, W. S., Johnson, D. C., Graham, F. L., and Rosenthal, K. L. (1993). Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. J. Infect. Dis. 168, 622-629.
17. Gao, M., and Knipe, D. M. (1989). Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J. Virol. 63, 5258-5267.
18. Gao, M., and Knipe, D. M. (1991). Potential role for herpes simplex virus ICP8 DNA replication protein in stimulation of late gene expression. J. Virol. 65, 2666-2675.
19. Gao, M., and Knipe, D. M. (1993). Intragenic complementation of herpes simplex virus ICP8 DNA-binding protein mutants. J. Virol. 67, 876-885.
20. Gressens, P., Langsten, C., and Martin, J. R. (1994). In situ PCR localization of herpes simplex virus DNA sequences in disseminated neonatal herpes encephalitis. J. Neuropathol. Exp. Neurol. 53, 469-482.
21. Gressens, P., and Martin, J. R. (1994). In situ polymerase chain reaction: Localization of HSV-2 DNA sequences in infections of the nervous system. J. Virol. Methods 46, 61-83.
22. Haase, A., Brahic, M., Stowring, L., and Blum, H. (1984). Detection of viral nucleic acids by in situ hybridization. Methods Virol. 7, 189-226.
23. Hammond, S. A., Bolinger, B. C., Stanhope, P. E., Quinn, T. C., Schwartz, D., Clements, M. L., and Siliciano, R. F. (1992). Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J. Exp. Med. 176, 1531-1542.
24. Harbour, D. A., Hill, T. J., and Blyth, W. A. (1981). Acute and recurrent herpes simplex in several strains of mice. J. Gen. Virol. 55, 31-40.
25. Heath, S. L., Tew, J. G., Szakal, A. K., and Burton, G. F. (1995). Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377, 740-744.
26. Hoggan, M. D., and Roizman, B. (1959). The isolation and properties of a variant of herpes simplex producing multinucleated giant cells in monolayer cultures in the presence of antibody. Am. J. Hyg. 70, 208-219.
27. Jacobson, J. G., Ruffner, K. L., Kosz-Vnenchak, M., Hwang, C. B., Wobbe, K. K., Knipe, D. M., and Coen, D. M. (1993). Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia. J. Virol. 67, 6903-6908.
28. Kennedy, P. G. E., Lisak, R. P., and McRaff. (1980). Cell type-specific markers for human glial and neuronal cells in culture. Lab. Invest. 43, 342-351.
29. Knipe, D. M., Quinlan, M. P., and Spang, A. E. (1982). Characterization of two conformational forms of the major DNA-binding protein encoded by herpes simplex virus 1. J. Virol. 44, 736-741.
30. Knipe, D. M., and Spang, A. E. (1982). Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus. J. Virol. 43, 314-324.
31. Langenberg, A., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., and Corey, L. (1995). A recombinant glycoprotein vaccine for herpes simplex type 2: Safety and efficacy. Ann. Int. Med. 122, 889-898.
32. Leib, D. A., Bogard, C. L., Kosz-Vnenchak, M., Hicks, K. A., Coen, D. M., Knipe, D. M., and Schaffer, P. A. (1989). A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency. J. Virol. 63, 2893-2900.
33. Leib, D. A., Nadeau, K. C., Rundle, S. A., and Schaffer, P. A. (1991). The promoter of the latency-associated transcripts of herpes simplex virus type 1 contains a functional cAMP-response element: Role of the latency-associated transcripts and cAMP in reactivation of viral latency. Proc. Natl. Acad. Sci. USA 88, 48-52.
34. Manservigi, R., Grossi, M. P., Gualandri, R., Balboni, P. G., Marchini, A., Rotola, A., Rimessi, P., Di Luca, D., Cassai, E., and Barbanti-Brodano, G. (1990a). Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector. J. Virol. 64, 431-436.
35. Manservigi, R., Incorvaia, C., Di Luca, D., Rotola, A., Balboni, P. G., Sebastiani, A., Rossi, A., and Cassai, E. (1990b). Experimental keratitis in rabbits by human HSV-1 variants: Prevention and treatment. J. Med. Virol. 32, 148-154.
36. McLean, C. S., Erturk, M., Jennings, R., Challanain, D. N., Minson, A. C., Duncan, I., Boursnell, M. E., and Inglis, S. C. (1994). Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170, 1100-1109.
37. Mehta, A., Maggioncalda, J., Bagasra, O., Thikkavarapu, S., Saikumari, P., Valyi-Nagy, T., Fraser, N. W., and Block, T. M. (1995). In situ PCR and RNA hybridization detection of herpes simplex virus sequences in trigeminal ganglia of latently infected mice. Virology 206, 633-640.
38. Meignier, B., Jourdier, T. M., Norrild, B., Pereira, L., and Roizman, B. (1987). Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: Protection against challenge with virulent virus. J. Infect. Dis. 155, 921-930.
39. Mertz, G. J., Peterman, G., Ashley, R., Jourden, J. L., Salter, D., Morrison, L., McLean, A., and Corey, L. (1984). Herpes simplex virus type-2 glycoprotein-subunit vaccine: Tolerance and humoral and cellular responses in humans. J. Infect. Dis. 150, 242-249.
40. Mertz, G. J., Ashley, R., Burke, R. L., Benedetti, J., Critchlow, C., Jones, C. C., and Corey, L. (1990). Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 161, 653-660.
41. Mims, C. A., Playfair, J. H. L., Roitt, I. M., Wakelin, D., and Williams, R. (1993). "Medical Microbiology," Mosby, St. Louis. 36.9.
42. Mishkin, E. M., Fahey, J. R., Kino, Y., Klein, R. J., Abramovitz, A. S., and Mento, S. J. (1991). Native herpes simplex virus glycoprotein D vaccine: Immunogenicity and protection in animal models. Vaccine 9, 147-153.
43. Morrison, L. A., and Knipe, D. M. (1994). Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. J. Virol. 68, 689-696.
44. Newell, C. K., Martin, S., Sendele, D., Mercadal, C. M., and Rouse, B. T. (1989). Herpes simplex virus-induced stromal keratitis: Role of T-lymphocyte subsets in immunopathology. J. Virol. 63, 769-775.
45. Nguyen, L. H., Knipe, D. M., and Finberg, R. W. (1992). Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J. Virol. 66, 7067-7072.
46. Paoletti, E., Lipinskas, B. R., Samsonoff, C., Mercer, S., and Panicali, D. (1984). Construction of live vaccines using genetically engineered poxviruses: Biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc. Natl. Acad. Sci. USA 81, 193-197.
47. Ramakrishnan, R., Levine, M., and Fink, D. J. (1994). PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant. J. Virol. 68, 7083-7091.
48. Reed, L. J., and Muench, H. A. (1938). A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
49. Rice, S. A., and Knipe, D. M. (1990). Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27. J. Virol. 64, 1704-1715.
50. Roizman, B. (1991). Introduction: Objectives of herpes simplex virus vaccines seen from a historical perspective. Rev. Infect. Dis. 13(Suppl. 11), S892-S894.
51. Rooney, J. F., Wohlenberg, C., Cremer, K. J., Moss, B., and Notkins, A. L. (1988). Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination. J. Virol. 62, 1530-1534.
52. Rud, E. W., Olgilvie, L., Clarke, B. E., Almond, N., Kent, K., Chan, L., Page, M., Kitchin, P., Stott, J., Cook, N., Sharpe, S., Ashworth, T., Dennis, M., Hall, G., and Cranage, M. P. (1994). A naturally attenuated SIVmac32H - Vaccine or Viral Interference. In "Vaccines 94" (E. Norrby, F. Brown, R. M. Chanock, and H. S. Ginsberg, Eds.), p. 217. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
53. Russell, E. S. (1966). "Biology of the Laboratory Mouse" (E. L. Green, Ed.), 2nd ed., pp. 511-519. McGraw-Hill, New York.
54. Stevens, J. G., Wagner, E. K., Devi-Rao, G. B., Cook, M. L., and Feldman, L. T. (1987). RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science 235, 1056-1059.
55. Stroop, W. G., Rock, D. L., and Fraser, N. W. (1984). Localization of herpes simplex virus in the trigeminal and olfactory systems of the mouse central nervous system during acute and latent infections by in situ hybridization. Lab. Invest. 51, 27-38.
56. Sutter, G., Wyatt, L. S., Foley, P. L., Bennink, J. R., and Moss, B. (1994). A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032-1040.
57. Wachsman, M., Luo, J. H., Aurelian, L., and Paoletti, E. (1992). Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D. Vaccine 10, 447-454.
58. Weir, J. P., Bennett, M., Allen, E. M., Elkins, K. L., Martin, S., and Rouse, B. T. (1989). Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J. Gen. Virol. 70, 2587-2594.
59. White, D. O., and Fenner, F. J. (1986). "Medical Virology," 3rd ed., pp. 283-303. Academic Press, New York.
60. Whitley, R. J. (1996). "Virology" (B. N. Fields, D. M. Knipe, and P. M. Howley, Eds.), 3rd ed., pp. 2297-2342. Lippincott-Raven, Philadelphia, PA.